Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08PBB
|
|||
| Former ID |
DNC000854
|
|||
| Drug Name |
L-694,458
|
|||
| Synonyms |
DMP 777; 157341-41-8; DMP-777; UNII-3Q0469283P; (S)-N-((R)-1-(Benzo[d][1,3]dioxol-5-yl)butyl)-3,3-diethyl-2-(4-(4-methylpiperazine-1-carbonyl)phenoxy)-4-oxoazetidine-1-carboxamide; DMP777; CHEMBL310871; L-694458; 3Q0469283P; (S)-N-((R)-1-(Benzo[d][1,3]dioxol-5-yl)butyl)-3,3-diethyl-2-(4-(4methyl-piperazine-1-carbonyl)phenoxy)-4-oxoazetidine-1-carboxamide (3.5% w/w solution); L-694,458; L 694458; SCHEMBL6538142; AC1L433D; CTK4C9348; DTXSID00166251; MolPort-023-332-820; C31H40N4O6; ZINC3936307; KS-00001E6Q; BCP02269
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cystic fibrosis [ICD-11: CA25; ICD-10: E84, E84.9; ICD-9: 277] | Phase 2 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C31H40N4O6
|
|||
| Canonical SMILES |
CCCC(C1=CC2=C(C=C1)OCO2)NC(=O)N3C(C(C3=O)(CC)CC)OC4=CC=C(C=C4)C(=O)N5CCN(CC5)C
|
|||
| InChI |
1S/C31H40N4O6/c1-5-8-24(22-11-14-25-26(19-22)40-20-39-25)32-30(38)35-28(37)31(6-2,7-3)29(35)41-23-12-9-21(10-13-23)27(36)34-17-15-33(4)16-18-34/h9-14,19,24,29H,5-8,15-18,20H2,1-4H3,(H,32,38)/t24-,29+/m1/s1
|
|||
| InChIKey |
ZSDCIRYNTCVTMF-GIGWZHCTSA-N
|
|||
| CAS Number |
CAS 157341-41-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10258824, 14812969, 14837631, 33501323, 76570568, 103284927, 103961532, 104426838, 126671449, 134339075, 134340163, 135154870, 142336332, 152258908, 160647754, 160832438, 162797666, 163397633, 163844255, 180100906, 184527598, 185972329, 189659308, 198958258, 204429446, 223660457, 232251389, 244216908, 251963056, 252504726
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Neutrophil elastase (NE) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Transcriptional misregulation in cancer | |||
| Systemic lupus erythematosus | ||||
| Pathway Interaction Database | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||
| C-MYB transcription factor network | ||||
| Reactome | Collagen degradation | |||
| Degradation of the extracellular matrix | ||||
| Activation of Matrix Metalloproteinases | ||||
| WikiPathways | Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | |||
| Human Complement System | ||||
| Degradation of collagen | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | New Drugs and Targets for Asthma and COPD, T.T. Hansel, .J. Barnes. Page(248). | |||
| REF 2 | Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs. 2002 Jul;11(7):965-80. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.